5 Under-the-Radar Stocks with Massive Upside for 2026

2. Legend Biotech Corporation (NASDAQ:LEGN)

Legend Biotech Corporation (NASDAQ:LEGN), with upside potential of 105.7%, ranks among the under-the-radar stocks with massive upside for 2026.

With continued CARVYKTI growth fueling a strong first quarter, Legend Biotech Corporation (NASDAQ:LEGN) is nearing adjusted profitability this year, drawing attention from multiple analysts.

On May 13, 2026, RBC Capital analyst Leonid Timashev raised the firm’s price target on Legend Biotech Corporation (NASDAQ:LEGN) to $64 from $62 and kept an “Outperform” rating following better-than-expected Q1 results. Timashev called it a good quarter for CARVYKTI, citing increasing penetration into earlier treatment lines, expansion into the community setting, and limited competitive pressure. HC Wainwright and Morgan Stanley also reiterated bullish ratings on the stock following the quarter.

Those analyst updates followed Legend Biotech Corporation (NASDAQ:LEGN)’s Q1 2026 results reported on May 12, 2026.

CARVYKTI net trade sales reached approximately $597 million, up 52% year-over-year, with U.S. sales growing 36% and ex-U.S. sales surging more than 200%. Total revenue came in at $305 million, with collaboration revenue from the Janssen partnership rising 61% to $298.4 million. Net loss narrowed to $54.3 million from $101.0 million a year earlier. Adjusted net loss improved to $10.5 million from $27.0 million, with Legend Biotech Corporation (NASDAQ:LEGN)’s management reaffirming guidance for company-wide adjusted profitability in 2026.

CARVYKTI is now approved in 18 global markets across more than 300 treatment sites. Legend Biotech Corporation (NASDAQ:LEGN) reported a 99% manufacturing success rate and a median turnaround time of approximately 29 days. Gross margin on net product sales declined to 41% from 57% the prior quarter, due to one-time expenses tied to manufacturing capacity expansion. CFO Carlos Santos said that without that charge, the company would have been profitable on an adjusted basis.

Cash, cash equivalents, and time deposits stood at approximately $835 million with no long-term debt.

Legend Biotech Corporation (NASDAQ:LEGN) is a commercial-stage biopharmaceutical company that develops innovative therapies. Being an end-to-end cell therapy company, they focus on medication for serious diseases such as hematologic malignancies and solid tumors.